Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 8NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 5Stomatitis 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mucositis 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 65Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 30Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Rituximab 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT02555644 2019-02-15

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Eli Lilly and Company

Phase 1 Completed
70 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡